Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PREDNISONE vs ACETASOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.
Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.
Allergic reactions (severe or incapacitating),Asthma,Chronic obstructive pulmonary disease (COPD) exacerbation,Collagen diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis),Dermatologic diseases (e.g., pemphigus, severe erythema multiforme),Endocrine disorders (e.g., adrenocortical insufficiency, congenital adrenal hyperplasia),Gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease),Hematologic disorders (e.g., autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura),Neoplastic diseases (e.g., leukemias, lymphomas),Nephrotic syndrome,Ophthalmic diseases (e.g., severe allergic conjunctivitis, keratitis),Organ transplantation (immunosuppression),Respiratory diseases (e.g., sarcoidosis, berylliosis),Rheumatic disorders (e.g., acute gouty arthritis, psoriatic arthritis),Tuberculous meningitis (with appropriate antituberculous therapy)
Treatment of superficial bacterial infections of the external auditory canal (swimmer's ear),Treatment of fungal infections of the external ear
5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.
5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.
Terminal half-life: 2-3 hours (plasma); clinical effects persist for 12-36 hours due to intracellular actions and active metabolite prednisolone (half-life 3-4 hours).
Hydrocortisone has a terminal elimination half-life of approximately 1.5-2 hours. Acetic acid has a half-life of minutes due to rapid metabolism. Clinical context: dosing interval is typically 3-4 times daily for otic use.
Hepatic, primarily via CYP3A4-mediated 6β-hydroxylation; also reduced by 20-ketosteroid reductases. Prednisone is a prodrug converted to active metabolite prednisolone.
Not extensively metabolized; undergoes minimal hepatic metabolism.
Renal: <10% as unchanged drug; hepatic metabolism to inactive glucuronide and sulfate conjugates; fecal: ~20-30% via biliary elimination.
Acetasol HC is a combination product containing hydrocortisone and acetic acid. Hydrocortisone is primarily metabolized in the liver and excreted renally as inactive metabolites; less than 1% is excreted unchanged. Acetic acid is rapidly metabolized via the tricarboxylic acid cycle and eliminated as carbon dioxide and water. Biliary/fecal elimination is negligible for both components.
Prednisone: 70-90% bound to albumin and corticosteroid-binding globulin (CBG); prednisolone: 60-70% bound.
Hydrocortisone is approximately 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid has negligible protein binding (<10%).
Vd: 0.5-1.0 L/kg; distributes widely, crosses placenta and enters breast milk; apparent Vd larger with hyperthyroidism.
Hydrocortisone Vd is approximately 0.3-0.5 L/kg, indicating distribution into total body water. Acetic acid Vd is approximately 0.4 L/kg. Clinical meaning: limited tissue distribution; primarily remains in extracellular fluid.
Oral: 70-80% (active prednisolone after hepatic conversion); IM: ~100%.
Otic: Bioavailability is approximately 10-20% via the ear canal due to slow permeation through tympanic membrane; systemic absorption is minimal (<10% of applied dose). Oral: Not applicable; product is for otic use only.
No dose adjustment required for renal impairment; consider alternative corticosteroid in severe renal disease if fluid retention is a concern.
No renal adjustment required as systemic absorption is negligible.
Child-Pugh A: no adjustment. Child-Pugh B or C: use with caution; dose reduction may be considered due to decreased clearance; monitor for adverse effects.
No hepatic adjustment required as systemic absorption is negligible.
0.1-2 mg/kg/day orally divided 1-4 times daily; maximum 60 mg/day; use lowest effective dose; for acute asthma, 1-2 mg/kg/day for 3-5 days.
Same as adult: 5 drops into affected ear(s) 3-4 times daily. Safety and efficacy in children under 2 years not established.
Start at lower end of dosing range (5-7.5 mg/day) due to increased risk of osteoporosis, hyperglycemia, and infections; monitor glucose and bone density; taper slowly to avoid adrenal suppression.
No specific adjustment; use same adult dosing. Consider age-related skin thinning and potential for increased systemic absorption in cases of tympanic membrane perforation.
None
None
Adrenal suppression and HPA axis suppression with prolonged therapy,Increased risk of infections,Exacerbation of systemic fungal infections,Masking of signs of infection,Osteoporosis with long-term use,Gastrointestinal perforation (especially in patients with certain GI disorders),Kaposi sarcoma reported,Cardiovascular effects (hypertension, fluid retention),Behavioral disturbances (euphoria, depression, psychosis),Posterior subcapsular cataracts and glaucoma,Thromboembolism risk,Vaccine response may be diminished; live vaccines contraindicated
For otic use only; not for ophthalmic use,Prolonged use may result in overgrowth of non-susceptible organisms,Discontinue if sensitization or irritation occurs,Caution in patients with perforated tympanic membrane
Systemic fungal infections,Hypersensitivity to prednisone or any component,Administration of live or live attenuated vaccines (due to immunosuppression)
Hypersensitivity to any component,Perforated tympanic membrane,Viral or fungal infections of the ear (except when used for fungal infections as indicated)
Avoid grapefruit juice as it may increase prednisone levels. Limit high-sodium foods to prevent fluid retention. Increase calcium and vitamin D intake to counteract bone loss. Avoid alcohol due to added GI irritation risk.
No known food interactions. Avoid excessive alcohol as it may impair immune response.
First trimester: Increased risk of cleft lip/palate (odds ratio 1.3-3.4). Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Chronic use: Dose-dependent fetal hypothalamic-pituitary-adrenal axis suppression.
ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies in pregnant women. Animal reproduction studies with topical glucocorticoids have shown an increased risk of cleft palate and other malformations at high doses. Based on limited human data and low systemic exposure, use during pregnancy is generally considered low risk. However, as a precaution, avoid use in the first trimester unless clearly needed.
Prednisone enters breast milk in low concentrations (M/P ratio ~0.25-0.5). Maternal doses ≤20 mg/day produce negligible infant exposure. Higher doses: Avoid breastfeeding for 4 hours after dose. Monitor infant for growth and adrenal suppression.
Systemic absorption after otic application is minimal. It is not known whether hydrocortisone or acetic acid is excreted in human milk. M/P ratio is not available. Concentrations in milk are likely negligible. Use is considered compatible with breastfeeding.
Minimal pharmacokinetic changes (slight increase in clearance). No routine dose adjustment needed. For acute indications, use lowest effective dose. For chronic conditions, increase dose may be needed in third trimester due to disease flare; taper postpartum.
No dose adjustment is necessary in pregnancy due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety of this topical otic preparation.
Prednisone is a prodrug converted to prednisolone; use prednisolone in severe hepatic impairment. Taper dose after prolonged use (≥3 weeks) to avoid adrenal crisis. Morning dosing mimics cortisol rhythm and reduces insomnia. Monitor for hyperglycemia, osteoporosis, avascular necrosis, and immunosuppression. Do not give live vaccines during therapy.
ACETASOL HC (acetic acid 2%, hydrocortisone 1%) is used for otitis externa. Acetic acid restores acidic p H of ear canal, inhibiting bacterial and fungal growth. Hydrocortisone reduces inflammation and pruritus. Ensure tympanic membrane is intact before use due to risk of ototoxicity with corticosteroids in middle ear. Do not use for more than 7 days. Shake well before instillation.
Take with food or milk to reduce stomach upset.,Do not stop abruptly; follow a tapering schedule from your doctor.,Notify your doctor if you experience fever, unusual bleeding, or weight gain.,Avoid live vaccines (e.g., MMR, nasal flu) while on prednisone.,Carry a steroid alert card or wear a medical ID bracelet.
Instill 3-4 drops into affected ear every 2-3 hours for 5-7 days.,Lie on side for 5 minutes after instillation to ensure coverage.,Avoid inserting cotton swabs or objects into the ear.,Discontinue if pain, worsening discharge, or rash occurs.,Do not use if ear drum is perforated or if you have a history of ear surgery.
"The combination of Droxicam, a nonsteroidal anti-inflammatory drug (NSAID) with potent COX-1/COX-2 inhibition, and the corticosteroid Prednisone results in an additive risk of gastrointestinal (GI) mucosal injury and bleeding. NSAIDs suppress protective prostaglandin synthesis in the gastric mucosa via COX-1 inhibition, while corticosteroids further impair mucosal defense and repair mechanisms, increasing the likelihood of peptic ulceration, GI perforation, and hemorrhage. Patients, particularly the elderly or those with prior GI disease, face a significantly elevated risk of serious adverse outcomes including upper GI bleeding and perforation."
"Cabergoline, a dopamine receptor agonist, can cause valvular heart disease due to its agonistic activity at serotonin 5-HT2B receptors on cardiac valves, leading to fibrotic changes. Prednisone, a corticosteroid, may potentiate this risk by suppressing inflammatory responses that could otherwise mitigate fibrotic progression, and by inducing catabolic effects that may exacerbate tissue vulnerability. Concurrent use may therefore increase the severity and progression of valvulopathy and other fibrotic complications."
"Concomitant use of Suprofen, a nonsteroidal anti-inflammatory drug (NSAID), with Prednisone, a corticosteroid, increases the risk of gastrointestinal (GI) adverse effects, including ulceration, bleeding, and perforation. This additive effect results from synergistic inhibition of prostaglandin-mediated protective mechanisms in the gastric mucosa, as both drug classes suppress COX enzymes and reduce mucosal defense. Patients, especially the elderly or those with a history of peptic ulcer disease, are at heightened risk for serious GI complications."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PREDNISONE vs ACETASOL HC, answered by our medical review team.
PREDNISONE is a Corticosteroid that works by Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.. ACETASOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PREDNISONE and ACETASOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PREDNISONE is: 5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.. The standard adult dose of ACETASOL HC is: 5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PREDNISONE and ACETASOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PREDNISONE is classified as Category D/X. First trimester: Increased risk of cleft lip/palate (odds ratio 1.3-3.4). Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Chronic use: Dose. ACETASOL HC is classified as Category C. ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.